44 results about "Myocarditis" patented technology

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.

The application provides an application of a FAP-targeted CAR-T cell in preparation of a drug for treating cardiac fibrosis in a chronic phase of myocarditis. It is found in the application that FAP-specific CAR-T cells can effectively target cells expressing mouse FAP proteins, and the CAR-T cells can effectively eliminate cells expressing mouse FAP proteins after being activated, the chimeric antigen receptor T cells effectively reduce cardiac fibrosis in a chronic phase of myocarditis in mice, and restore the function after inflammatory injury. The application develops a CAR-T therapy for myocardial fibrosis caused by a chronic phase of myocarditis, and the chimeric antigen receptor T cells expressing a targeted fibroblast activation protein can recognize activated myocardial fibroblasts, and significantly reduce cardiac fibrosis after inflammatory injury and restore the function.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed.

This invention discloses a myocarditis treatment prediction system integrating Transformer and causal reinforcement learning, comprising a data preprocessing module, a temporal encoding module, a causal decision-making module, and an interpretation regularization module. The data preprocessing module transforms multimodal clinical data into equally spaced state representation sequences; the temporal encoding module extracts global temporal dependencies through the multi-head self-attention mechanism of a Transformer encoder, outputting an abstract state vector; the causal decision-making module uses the abstract state vector as input to construct a Markov decision process, employs offline strategies to evaluate and estimate the expected clinical benefits of different intervention timings, and outputs individualized intervention recommendations and confidence levels through policy gradient optimization. This invention can capture the dynamic evolution of myocarditis disease under limited case conditions, assess the causal effects of different intervention strategies without real clinical trials, and provides a transparent and interpretable decision-making process, effectively assisting clinicians in identifying the optimal timing for immunosuppressive therapy.

The invention discloses a polypeptide for inducing immune myocarditis and application of the polypeptide. The polypeptide comprises an amino acid sequence as shown in at least one of SEQ ID NO. 1 to SEQ ID NO. 39. The polypeptide has obvious immunogenicity and inflammatory potential, and can be used as a stable and repeatable immune myocarditis induction system.

The present invention belongs to the technical field of vaccines and relates to an encephalomyocarditis multi-epitope recombinant protein, and the encephalomyocarditis multi-epitope recombinant protein comprises 8 B-cell epitopes and 1 signal peptide. The present invention also provides the application of the recombinant protein in the preparation of an encephalomyocarditis vaccine. With the goal of developing a safe and effective vaccine, the B-cell epitopes of VP1, VP2, and VP3 of the EMCV structural protein are screened, and a recombinant epitope protein with good hydrophilicity, strong antigenicity, and high surface accessibility is constructed. By immunizing BALB / c mice, it is found that it can induce the production of neutralizing antibodies and a Th1-dominated cellular immune response, and can protect the mice from EMCV attack. The results show that the MIgH-EMCV-II<supgt;2D2< / supgt; protein may be a potential candidate for developing a safe and effective multi-epitope vaccine to control EMCV infection.

The invention relates to the technical field of biological medicines, in particular to application of a TRIM28-ERVs pathway negative regulator in treatment of myocarditis and heart failure. According to the invention, the important effect of the TRIM28-ERVs pathway negative regulator in treating myocarditis and heart failure is found for the first time, so that a new medicine for treating myocarditis and heart failure can be found.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The invention discloses a traditional Chinese medicine composition and application thereof. The composition comprises 8-12 parts of agastache rugosus, 4-8 parts of fructus gleditsiae, 8-12 parts of radix angelicae, 8-12 parts of pericarpium citri reticulatae, 4-8 parts of mint, 4-8 parts of liquorice, 8-12 parts of platycodon grandiflorum, 4-8 parts of radix aucklandiae, 8-12 parts of radix saposhnikoviae, 4-8 parts of pinellia ternate, 0.1-0.5 part of realgar, 8-12 parts of radix ampelopsis, 8-12 parts of notopterygium root, 8-12 parts of radix bupleuri, 8-12 parts of scutellaria baicalensis, 4-8 parts of coptis chinensis, 8-12 parts of golden cypress, 8-12 parts of poria cocos, 8-12 parts of rhizoma alismatis, 8-12 parts of fructus aurantii, 8-12 parts of radix scrophulariae and 4-8 parts of The traditional Chinese medicine composition can be used for treating or preventing fever, respiratory tract diseases, digestive tract diseases or myocarditis caused by viruses, bacteria or fungi, and has the advantages of scientific formula and exact curative effect.

The novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are NLRP3 inhibitors and may be useful in the treatment, prevention, management, improvement, control, and suppression of NLRP3-mediated diseases. The compounds of the present invention may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (LBD), and traumatic brain injury. (I)

An apparatus and method for detecting a level of cardiovascular disease. The apparatus includes at least a processor and a memory communicatively connected to the at least a processor, wherein the memory contains instructions configuring the at least a processor to: receive a plurality of voltage-time data, generate at least a feature vector from the voltage-time data by at least a feature model, input the at least feature vector into a cardiovascular classification model, generate at least a disease indication in a subject using the classification model, wherein the disease indication comprises a level of myocarditis, and display the at least a disease indication.

The present invention provides biomarkers for predicting immune-related myasthenia gravis, myocarditis, and myositis. The key locus HLA-DQB1 * 03: 03 is obtained through HLA typing, and the method has a good prediction value on whether tumor patients subjected to ICI treatment suffer from irMG and / or myositis and myocarditis or not. The invention provides a screening tool which can identify a potential high-risk irAE patient before ICI treatment, and provides inspiration for preventive treatment development of irMG susceptible people.

The present invention provides the use of a CCR2 antagonist in the treatment of myocarditis, particularly in the treatment of immune checkpoint inhibitor-associated myocarditis. The present invention also provides a pharmaceutical composition comprising a CCR2 antagonist and 5-aminosalicylic acid, and its use in the treatment of immune checkpoint inhibitor-associated myocarditis. When the CCR2 antagonist and 5-aminosalicylic acid are administered in combination, the therapeutic effect of myocarditis is enhanced.

The invention relates to the technical field of disease model construction, and discloses a method for constructing a myocarditis organ disease model, which comprises the following steps: carrying out first-stage culture on human induced pluripotent stem cells in a culture medium M1 containing a GSK-3beta inhibitor, and then carrying out second-stage culture by using a culture medium M2 containing VEGFA (Vascular Endothelial Growth Fatty Acid) to obtain a stably pulsatile cell aggregate; and performing third-stage culture on the cell aggregate in a lipopolysaccharide-containing culture medium M3 to obtain the myocarditis organ disease model. According to the method, three specific culture media are sequentially adopted, construction from hiPSC to the myocarditis organ disease model can be achieved, and the construction process is efficient, rapid, simple and convenient.

This invention relates to the field of biodetection technology, specifically to a multimodal miRNA detection array based on Mn-CeO2@CDs nanozymes and Cas12a sensing, its preparation method, and its applications. The recognition and signal amplification probe composition based on Mn-CeO2@CDs nanozymes and Cas12a includes: a solid substrate, the DNA Y-shaped structure described in the first aspect, the composite nanozyme, and a CRISPR / Cas12a system. This invention combines DNA nanotechnology, Cas12a enzyme digestion technology, and nanozymes as signal output mediators, achieving highly specific and sensitive multimodal detection of myocarditis biomarkers (miRNAs) in fluorescence, UV-visualization, and electrochemical modes.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of an ICI-related myocarditis mouse model closer to clinical application. The ICI-related myocarditis mouse model closer to clinical application is successfully constructed by constructing a liver metastatic tumor model of a C57BL / 6 mouse and then injecting ICIs. The construction method provided by the invention has the advantages of simplicity in operation, low cost and high modeling rate (50-60%), and the ICI-related myocarditis mouse model constructed by the method is closer to clinical application. Meanwhile, the ICI-related myocarditis mouse model obtained by the construction method provided by the invention can also be used for ICI-related myocarditis model mechanism research, ICI-related myocarditis drug screening or ICI-related myocarditis treatment method development and the like.

Methods for treating leukocytosis, endothelial dysfunction, and carditis comprising administering to a subject a lipid binding protein-based complex.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

Disclosed herein are methods and materials for treating myocarditis with gene therapy. In some cases, disclosed herein are methods and material for treating myocarditis in a subject in need thereof comprising administering to the subject an effective amount of a vector comprising a nucleic acid sequence encoding a connexin 43 polypeptide operably linked to a promoter active in cardiac muscle tissue. Also disclosed herein are methods of treating myocarditis by administering to a subject an agent that increases the level of a connexin 43 encoding nucleic acid molecule or connexin 43 polypeptide.

The invention provides antibody functionalized Au and Raman signal molecule and Au nanoparticles, a sandwich structure formed by combining magnetic beads and nanoparticles and application of the sandwich structure, and belongs to the technical field of myocarditis related index detection. A Raman signal molecule is introduced into the surface of a gold nanoparticle, a gold shell layer is deposited, the surface of the gold shell layer is modified with an antibody, and the antibody functionalized Au and Raman signal molecule and Au nanoparticle is constructed. According to the invention, the silver-coated gold nanoparticles are prepared, silver on the outer layers of the silver-coated gold nanoparticles can be etched while the silver-coated gold nanoparticles and a second part of HAuCl4 are subjected to reduction reaction to coat a gold shell layer, and a nano cavity with extremely strong hot spots is formed between an inner-layer nano gold core and an outer-layer gold shell, so that amplification can be realized, and repeatable Raman signal reading can be realized; and accurate detection is promoted. The sandwich structure formed by further combining the magnetic beads and the nanoparticles can accurately and quickly realize Raman spectrum identification of five positive and negative samples of myocarditis.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The present invention relates to AZD1656 or a pharmaceutically acceptable salt thereof for use in the treatment of pneumonia and / or myocarditis that may be associated with or caused by coronavirus infection.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention discloses a passiflora edulis seed oil extract and application thereof in preparation of a medicine for treating myocarditis, and the passiflora edulis seed oil extract is obtained by performing saponification reaction on passiflora edulis seed oil and alkali and extracting with an organic solvent. The passion flower seed oil extract can reduce the expression of p65-NF-kappa B, T-JNK, P-JNK and TNF-alpha proteins, so as to prevent and / or treat myocarditis and related diseases thereof. Besides, the passion flower seeds are used as the raw material, waste utilization is achieved, waste is turned into wealth, the extraction method is simple in step, simple, convenient and rapid, the raw material utilization rate is high, and the cost of passion flower related products can be effectively reduced.

An object of the present invention is to provide a novel composition for treating myocarditis and / or a novel composition for preventing the myocarditis. A composition containing an inhibitor of VLA-4 for preventing or treating the myocarditis is provided.

The invention provides a novel ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound shown in the formula I and having a good inhibition effect on ferroptosis, and the compound can be used for preparing a ferroptosis inhibitor. The compound can also be used for preparing medicines for treating diseases such as ischemia-reperfusion injury, drug-induced liver injury, acute kidney injury, renal failure, hepatic pulmonary fibrosis, neurodegenerative diseases, cerebral apoplexy, myocarditis, myocardial infarction, heart failure, arthritis, chronic atrophic gastritis and the like related to ferroptosis, and has a wide market prospect.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.